In vivo effect of α-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice

Oncology Research

Volumn 18, Issue 9, 2010, Pages 409-418

  Costarelli, Laura ^a   Malavolta, Marco ^a   Giacconi, Robertina ^a   Cipriano, Catia ^a   Gasparini, Nazzarena ^a   Tesei, Silvia ^a   Pierpaoli, Sara ^a   Orlando, Fiorenza ^a   Suzuki, Hisanori ^b   Perbellini, Luigi ^b   Piacenza, Francesco ^c   Emanuelli, Monica ^c   Mocchegiani, Eugenio ^a  

^a INRCA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adjuvant therapy; Array analysis; Breast cancer; HER 2 neu; Natural substances

Indexed keywords

BISABOLOL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 1; I KAPPA B KINASE BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; OSTEOPONTIN; PROTEIN BIRC5; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INCIDENCE; CANCER SURGERY; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; GENE CONTROL; GENE EXPRESSION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 77952327851     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12671222663557     Document Type: Article

References (32)

1. Chung, S. Y.; Sung, M. K.; Kim, N. H.; Jang, J. O.; Go, E. J.; Lee, H. J. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch. Pharm. Res. 28:823-828; 2005.
2. Provinciali, M.; Papalini, F.; Orlando, F.; Pierpaoli, S.; Donnini, A.; Morazzoni, P.; Riva, A.; Smorlesi, A. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. Cancer Res. 67:2022-2029; 2007.
3. Roy, A. M.; Baliga, M. S.; Katiyar, S. K. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol. Cancer Ther. 4:81-90; 2005.
4. McLachlan, A.; Kekre, N.; McNulty, J.; Pandey, S. Pancratistatin: A natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 10:619-630; 2005.
5. Jakovlev, V.; Von Schlichtegroll, A. On the inflammation inhibitory effect of (-)-alpha-bisabolol; an essential component of chamomilla oil. Arzneimittelforschung 19:615-616; 1969.
6. Jakovlev, V.; Isaac, O.; Thiemer, K.; Kunde, R. Pharmacological investigations with compounds of chamomile ii. New investigations on the antiphlogistic effects of (-)-alpha-bisabolol and bisabolol oxides (author's transl). Planta Med. 35:125-140; 1979.
7. Cavalieri, E.; Mariotto, S.; Fabrizi, C.; De Prati, A. C.; Gottardo, R.; Leone, S.; Berra, L. V.; Lauro, G. M.; Ciampa, A. R.; Suzuki, H. alpha-Bisabolol, a nontoxic natural compound, strongly induces apoptosis in glioma cells. Biochem. Biophys. Res. Commun. 315:589-594; 2004.
8. Hernández-Ceruelos, A.; Madrigal-Bujaidar, E.; De la Cruz, C. Inhibitory effect of chamomile essential oil on the sister chromatid exchanges induced by daunorubicin and methyl methanesulfonate in mouse bone marrow. Toxicol. Lett. 135:103-110; 2002.
9. Darra, E.; Abdel-Azeim, S.; Manara, A.; Shoji, K.; Maréchal, J. D.; Mariotto, S.; Cavalieri, E.; Perbellini, L.; Pizza, C.; Perahia, D.; Crimi, M.; Suzuki, H. Insight into the apoptosis-inducing action of alpha-bisabolol towards malignant tumor cells: Involvement of lipid rafts and Bid. Arch. Biochem. Biophys. 476:113-123; 2008.
10. Russin, W. A.; Hoesly, J. D.; Elson, C. E.; Tanner, M. A.; Gould, M. N. Inhibition of rat mammary carcinogenesis by monoterpenoids. Carcinogenesis 10:2161-2164; 1989.
11. Engel, R. H.; Kaklamani, V. G. HER2-positive breast cancer: current and future treatment strategies. Drugs 679: 1329-1341; 2007.
12. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-792; 2001.
13. Piccart, M.; Lohrisch, C.; Di Leo, A.; Larsimont, D. The predictive value of HER2 in breast cancer. Oncology 61: 73-82; 2001.
14. Schechter, A. L.; Stern, D. F.; Vaidyanathan, L.; Decker, S. J.; Drebin, J. A.; Greene, M. I.; Weinberg, R. A. The neu oncogene: An erb-B-related gene encoding a 185;000-Mr tumour antigen. Nature 312:513-516; 1984.
15. Muller, W. J.; Sinn, E.; Pattengale, P. K.; Wallace, R.; Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115; 1988.
16. Provinciali, M.; Di Stefano, G.; Fabris, N. Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR release assay. J. Immunol. Methods 155:19-24; 1992.
17. Bryant, J.; Day, R.; Whiteside, T. L.; Herberman, R. B. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J. Immunol. Methods 146:91-103; 1992.
18. Fang, S. H.; Padmavathi, V.; Rao, Y. K.; Venkata Subbaiah, D. R.; Thriveni, P.; Geethangili, M.; Padmaja, A.; Tzeng, Y. M. Biological evaluation of sulfone derivatives as anti-inflammatory and tumor cells growth inhibitory agents. Int. Immunopharmacol. 6:1699-1705; 2006.
19. Budavari, S. The Merck index, 12th ed. Whitehouse Station, NJ: Merck Research Laboratories Division of Meck and Co., Inc.; 1996.
20. Zhang, S.; Won, Y. K.; Ong, C. N.; Shen, H. M. Anticancer potential of sesquiterpene lactones: Bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents 5:239-249; 2005.
21. Wen, J.; You, K. R.; Lee, S. Y.; Song, C. H.; Kim, D. G. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem. 277:38954-38964; 2002.
22. Herbermann, R. B.; Ortaldo, J. R. Natural killer cells. Their role in defences against disease. Science 214:24-30; 1981.
23. Wu, J. T.; Kral, J. G. The NF-kappaB/IkappaB signaling system: A molecular target in breast cancer therapy. J. Surg. Res. 123:158-169; 2005.
24. Ma, G.; Tabanca, N.; Husnu Can Baser, K.; Kirimer, N.; Pasco, D. S.; Khan, I. A.; Khan, S. I. Inhibition of NF-kappaB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2- methyl butyrate. Cancer Chemother. Pharmacol. 63: 673-680; 2009.
25. Sun, X. F.; Zhang, H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol. Histopathol. 22:1387-1398; 2007.
26. Biswas, D. K.; Cruz, A. P.; Gansberger, E.; Pardee, A. B. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA 97:8542-8547; 2000.
27. Ma, L.; Gauvillé, C.; Berthois, Y.; Degeorges, A.; Millot, G.; Martin, P. M.; Calvo, F. Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells. Int. J. Cancer 78:112-119; 1998.
28. Naderi, A.; Hughes-Davies, L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10: 542-548; 2008.
29. Bandyopadhyay, A.; Wang, L.; Chin, S. H.; Sun, L. Z. Inhibition of skeletal metastasis by ectopic ERα expression in ERα-negative human breast cancer cell lines. Neoplasia 9:113-118; 2007.
30. Biswas, D. K.; Iglehart, J. D. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J. Cell. Physiol. 209:645-652; 2006.
31. Amundadottir, L. T.; Leder, P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16:737-746; 1998.
32. Yoshimura, N.; Sano, H.; Hashiramoto, A.; Yamada, R.; Nakajima, H.; Kondo, M.; Oka, T. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin. Immunol. Immunopathol. 89:28-34; 1998.